skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Nome da Publicação: Pr Newswire remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer

PR newswire, 2024-06-02

PR Newswire Association LLC

Sem texto completo

Citações Citado por
2
Innovent Announces Taletrectinib­eROS1 Inhibitor­eUpdated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
Innovent Announces Taletrectinib­eROS1 Inhibitor­eUpdated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Innovent Announces Taletrectinib­eROS1 Inhibitor­eUpdated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

PR newswire, 2024-06-02

PR Newswire Association LLC

Sem texto completo

Citações Citado por
3
Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting
Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting

PR newswire, 2024-06-02

PR Newswire Association LLC

Sem texto completo

Citações Citado por
4
Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma
Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma

PR newswire, 2024-06-02

PR Newswire Association LLC

Sem texto completo

Citações Citado por
5
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

PR newswire, 2024-06-01

PR Newswire Association LLC

Sem texto completo

Citações Citado por
6
GenFleet Therapeutics Announces Efficacy Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
GenFleet Therapeutics Announces Efficacy Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

GenFleet Therapeutics Announces Efficacy Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

PR newswire, 2024-06-01

PR Newswire Association LLC

Sem texto completo

Citações Citado por
7
Hyundai Motor America Reports May 2024 Sales
Hyundai Motor America Reports May 2024 Sales
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Hyundai Motor America Reports May 2024 Sales

PR newswire, 2024-06-01

PR Newswire Association LLC

Sem texto completo

Citações Citado por
8
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

PR newswire, 2024-06-01

PR Newswire Association LLC

Sem texto completo

Citações Citado por
9
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib­eROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib­eROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib­eROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

PR newswire, 2024-06-01

PR Newswire Association LLC

Sem texto completo

Citações Citado por
10
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
Material Type:
Artigo de Jornal 		Adicionar ao Meu Espaço

Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer

PR newswire, 2024-06-01

PR Newswire Association LLC

Sem texto completo

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de1997  (1.649)
  2. 1997Até2002  (5.020)
  3. 2003Até2008  (3.943)
  4. 2009Até2015  (48.677)
  5. Após 2015  (99.999)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.